Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic profiling of hepatocellular carcinoma using next-generation sequencing
Kornelius Schulze, Jean–Charles Nault, Augusto Villanueva
Journal of Hepatology (2016) Vol. 65, Iss. 5, pp. 1031-1042
Open Access | Times Cited: 257

Showing 1-25 of 257 citing articles:

Hepatocellular carcinoma
Alejandro Forner, María Reig, Jordi Bruix
The Lancet (2018) Vol. 391, Iss. 10127, pp. 1301-1314
Closed Access | Times Cited: 4627
Hepatocellular Carcinoma
Augusto Villanueva
New England Journal of Medicine (2019) Vol. 380, Iss. 15, pp. 1450-1462
Closed Access | Times Cited: 3649
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia, Augusto Villanueva, Scott L. Friedman, et al.
Gastroenterology (2016) Vol. 152, Iss. 4, pp. 745-761
Open Access | Times Cited: 1009
Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
Otília Menyhárt, Ádám Nagy, Balázs Győrffy
Royal Society Open Science (2018) Vol. 5, Iss. 12, pp. 181006-181006
Open Access | Times Cited: 427
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Gonzalo Sapisochín, Jordi Bruix
Nature Reviews Gastroenterology & Hepatology (2017) Vol. 14, Iss. 4, pp. 203-217
Closed Access | Times Cited: 391
Global Epidemiology and Genetics of Hepatocellular Carcinoma
Ming Ren Toh, Evelyn Wong, Sunny H. Wong, et al.
Gastroenterology (2023) Vol. 164, Iss. 5, pp. 766-782
Closed Access | Times Cited: 293
A targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Fan Yao, Yalan Deng, Yang Zhao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 199
The role of telomeres and telomerase in cirrhosis and liver cancer
Jean–Charles Nault, Massih Ningarhari, Sandra Rebouissou, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 9, pp. 544-558
Closed Access | Times Cited: 194
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
Josep M. Llovet, Robert Montal, Augusto Villanueva
Journal of Hepatology (2019) Vol. 70, Iss. 6, pp. 1262-1277
Open Access | Times Cited: 182
Insights into the success and failure of systemic therapy for hepatocellular carcinoma
Jordi Bruix, Leonardo Gomes da Fonseca, María Reig
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 10, pp. 617-630
Closed Access | Times Cited: 177
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma
Jean–Charles Nault, Yoann Martin, Stefano Caruso, et al.
Hepatology (2019) Vol. 71, Iss. 1, pp. 164-182
Closed Access | Times Cited: 159
Molecular Bases of Drug Resistance in Hepatocellular Carcinoma
José J.G. Marı́n, Rocı́o I.R. Macı́as, María J. Monte, et al.
Cancers (2020) Vol. 12, Iss. 6, pp. 1663-1663
Open Access | Times Cited: 156
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
Amit G. Singal, Yujin Hoshida, David J. Pinato, et al.
Gastroenterology (2021) Vol. 160, Iss. 7, pp. 2572-2584
Open Access | Times Cited: 125
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Xiaoting Luo, Xin He, Xingmei Zhang, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 33
Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
Celina Ang, Samuel J. Klempner, Siraj M. Ali, et al.
Oncotarget (2019) Vol. 10, Iss. 40, pp. 4018-4025
Open Access | Times Cited: 141
Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer
Chinthalapally V. Rao, Adam S. Asch, Hiroshi Yamada
Carcinogenesis (2016) Vol. 38, Iss. 1, pp. 2-11
Open Access | Times Cited: 131
Mutational landscape of a chemically-induced mouse model of liver cancer
Frances Connor, Tim F. Rayner, Sarah J. Aitken, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 4, pp. 840-850
Open Access | Times Cited: 124
Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma
Jingxian Gu, Xing Zhang, Runchen Miao, et al.
World Journal of Gastroenterology (2019) Vol. 25, Iss. 2, pp. 220-232
Open Access | Times Cited: 113
Signaling pathways in hepatocellular carcinoma
Teresa García‐Lezana, Juan L López-Cánovas, Augusto Villanueva
Advances in cancer research (2020), pp. 63-101
Closed Access | Times Cited: 111
Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma
Lindsey N. Kent, Sooin Bae, Shih‐Yin Tsai, et al.
Journal of Clinical Investigation (2017) Vol. 127, Iss. 3, pp. 830-842
Open Access | Times Cited: 110
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
Sirish Dharmapuri, Umut Özbek, Jung‐Yi Lin, et al.
Cancer Medicine (2020) Vol. 9, Iss. 14, pp. 4962-4970
Open Access | Times Cited: 108
Systemic Treatment for Advanced Hepatocellular Carcinoma
Mohamed Bouattour, Neil Mehta, Aiwu Ruth He, et al.
Liver Cancer (2019) Vol. 8, Iss. 5, pp. 341-358
Open Access | Times Cited: 104
Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
Juliane Lokau, V. Schoeder, Johannes Haybaeck, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1704-1704
Open Access | Times Cited: 104
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma
Amanda Garrido, Nabil Djouder
Trends in cancer (2020) Vol. 7, Iss. 1, pp. 29-36
Closed Access | Times Cited: 101
EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1
Dong Jun Park, Pil Soo Sung, Jung‐Hee Kim, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000301-e000301
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top